# MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis

> **NCT04680962** · PHASE3 · WITHDRAWN · sponsor: **Mabion SA**

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** MabionCD20 (candidate biosimilar to rituximab)
- **BIOLOGICAL:** MabThera®
- **BIOLOGICAL:** Rituxan®

## Key facts

- **NCT ID:** NCT04680962
- **Lead sponsor:** Mabion SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-08-03
- **Primary completion:** 2023-08-03
- **Final completion:** 2023-08-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study closed for business reasons before patient recruitment was initiated.
- **Last updated:** 2023-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04680962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04680962, "MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04680962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*